Complex | |
AACDB_ID: | 1543 |
PDBID: | 5L6Y |
Chains: | HL_C |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 1.99 |
Reference: | 10.1016/j.jmb.2016.12.005 |
Antibody | |
Antibody: | tralokinumab Fab |
Antibody mutation: | No |
INN (Clinical Trial): | Tralokinumab(Approved) |
Antigen | |
Antigen: | Interleukin-13 |
Antigen mutation: | No |
Durg Target: | P35225 |
Antibody
Heavy Chain: H
Mutation: NULL
>5L6Y_H|Chain B[auth H]|tralokinumab FAb digest VH|Homo sapiens (9606) QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSSASTKGPSVFPLAPISKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVGPSSSLGTQTYICNVNHKPSNTKVDKRVESKYGPPSPSSPAPAKN |
Light Chain: L
Mutation: NULL
>5L6Y_L|Chain C[auth L]|tralokiumab FAb digest VL|Homo sapiens (9606) SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
Antigen
Chain: C
Mutation: NULL
>5L6Y_C|Chain A[auth C]|Interleukin-13|Homo sapiens (9606) GPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
L: ILE27 GLY29 SER30 LYS31 LEU32 HIS34 ASP50 ASP51 ASP53 ASN66 SER67 GLY68 ASN69 TRP91 THR93 C: SER6 ARG10 ILE13 GLU14 VAL17 THR20 GLN21 ASN22 LEU99 LEU100 LYS103 LYS104 PHE106 ARG107 GLU108 GLY109 PHE111 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)